HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 323 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,916,265 | -25.1% | 50,164 | -29.2% | 0.01% | -27.3% |
| Q2 2023 | $2,557,147 | -20.5% | 70,894 | -15.8% | 0.01% | -21.4% |
| Q1 2023 | $3,216,515 | +41521.6% | 84,224 | -38.0% | 0.01% | -61.1% |
| Q4 2022 | $7,728 | +43.9% | 135,812 | 0.0% | 0.04% | +38.5% |
| Q3 2022 | $5,370 | -99.9% | 135,812 | +7.8% | 0.03% | 0.0% |
| Q2 2022 | $5,544,000 | +110.6% | 126,009 | +90.9% | 0.03% | +160.0% |
| Q1 2022 | $2,632,000 | +16.9% | 66,009 | +17.9% | 0.01% | +25.0% |
| Q4 2021 | $2,252,000 | -1.2% | 56,009 | 0.0% | 0.01% | -11.1% |
| Q3 2021 | $2,279,000 | -18.5% | 56,009 | -9.1% | 0.01% | -18.2% |
| Q2 2021 | $2,797,000 | -52.6% | 61,587 | -56.5% | 0.01% | -54.2% |
| Q1 2021 | $5,903,000 | +25.6% | 141,587 | +28.7% | 0.02% | +20.0% |
| Q4 2020 | $4,698,000 | – | 110,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |